BioSpace News Archive

- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Zynerba’s Chief Executive Officer, Armando Anido will present a company overview at the virtual 40th Annual Canaccord Genuity Growth Conference. The presentation will take place on Wednesday, August 12, 2020 at 4:30PM EDT. This meeting is being held

ANNOVERA® prescriptions increased approximately 100% for the eight weeks ended July 24, 2020 over the previous eight week period

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company is scheduled to present at the virtual Canaccord 40 th Annual Growth Conference on Thursday, August 13, 2020 at 1:00 p.m. ET. A live webcast of the presentation can be accessed under “Events & Presentations” in the Investors section of the company’s website at www.agios.com.

Regulatory and Clinical Progress in MLD, MPS-I and MPS-IIIA Illustrate Execution in Neurometabolic Disorders; EU Regulatory Decision for Libmeldy ™ Expected in 2H 2020 MolMed and GSK Agreements Provide Near-term Manufacturing Capacity and Highlight Future Innovations Near-term Financial Position Secure with Cash and Investments of ~$230M and Runway into 2022 BOSTON and LONDON, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, to

BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology, today announced that Dr. Vimal Mehta, Founder and Chief Executive Officer of BTI, will participate in a virtual fireside chat at the Canaccord Genuity 40th Annual Growth Conference. Presentation Details: Event: Canaccord Genuity 4

Second Quarter 2020 Revenue of $32.4 Million, a 14% Increase Compared to Second Quarter 2019 Second Quarter 2020 Net Income of $2.2 Million as Compared to Net Loss of $2.2 Million for Second Quarter 2019 Reinstates Full-Year 2020 Revenue Guidance Range of $135 to $155 Million EWING, N.J., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a pharmaceutical technology company, today reported operating and financial results for the second quar

Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that it has entered into a $50 million Revenue Interest Financing (“RIF”) agreement with Sagard Healthcare Royalty Partners, LP (“SHRP”), a division of multi-strategy alternative asset manager Sagard Holdings (the “Agreement”). The Com

MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced financial results for the second quarter ended June 30, 2020 and provided business and financial updates related to the COVID-19

Key Highlights: Net sales revenue increased approximately 11% to $6.4 million Gross profit continues to show improvement year-over-year as a result of targeted actions to improve margins and cost structure Operating loss improved by approximately $276 thousand Adjusted EBITDA improved 21% Appointed new CEO, James A. Mish and new CFO, John Franzino WILLIAMSVILLE, N.Y., Aug. 06, 2020 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII) (“22nd Century” or “the Company”), a

Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today reported financial results for its fiscal 2020 third quarter. “It is an accomplishment having three ongoing